Titan Medical Corporate Presentation.

7/23/2019 Titan Medical Corporate Presentation.

http://slidepdf.com/reader/full/titan-medical-corporate-presentation 1/18

1

Titan Medical Inc.

Corporate Presentation

TSX: TMD | OTCQX: TITXF

November 24, 2015



2

This presentation contains "forward-looking statements" which reflect the current expectations of

management of the Company's future growth, results of operations, technological development and

implementation, performance and business prospects, opportunities, and illustrations and prototypes of the

SPORT™ Surgical Systems. Wherever possible, words such as "may", "would", "could", "will", "anticipate",

"believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these

forward-looking statements. These statements reflect management's current beliefs with respect to future

events and are based on information currently available to management. Forward-looking statements involve

significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results,

performance, achievements or technological development and implementation to be materially different from

any future results, performance, achievements or technological development and implementation that may beexpressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk

Factors" section of the Company's Annual Information Form dated March 31, 2015 and other information

contained in the Company’s public filings (which may be viewed at www.sedar.com). Information contained in

this presentation is qualified in its entirety by such public filings. Should one or more of these risks or

uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect,

actual results, performance or achievements may vary materially from those expressed or implied by the

forward-looking statements contained in this presentation. These factors should be considered carefully andprospective investors should not place undue reliance on the forward-looking statements. Although the

forward-looking statements contained in the presentation are based upon what management currently

believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results,

performance or achievements will be consistent with these forward-looking statements. This presentation

does not constitute an offer to sell any class of securities of the Company in any jurisdiction.

Forward Looking Statements



3

Titan’s SPORT™ Surgical System

Artist/CAD Rendering of SPORT™ Surgical System*The SPORT™ Surgical System has not been approved for sale or use by any regulatory authority, including the FDA.



4

• Focused on meeting the Customers’ Needs inRobotic Surgery

– Capital cost – too expensive

– Cost per case – too high

– Lack of mobility reduces operational efficiency

– Return on investment – not realized in many programs

• Efficiency – color coding instruments, etc.

– Training programs need improvement

– Customer support and service

• Data collection and analytics

Titan Strategy



5

• The SPORT™ Surgical System delivers next generation

computer-assisted robotic surgical technology thatbuilds on traditional robotic surgical features:

– Tele-operation

– 3D stereoscopic imaging

– Restoration of instinctive control

• The SPORT™ Surgical System is designed to provide:

– An advanced workstation incorporating a 3D high definitiondisplay providing a more ergonomic friendly user interface

– Improved instrument dexterity

– Single incision access

The SPORT™ Surgical System



6

Two Main Components:

SPORT™ Surgical System CAD Rendering

Patient CartSurgeon Workstation

The SPORT™ Surgical System



Surgeon Workstation

SPORT™ Surgical System

Workstation CAD Rendering

• Advanced ergonomic surgeon interface

to allow the surgeon to more comfortablycontrol the surgical platform.

– The system adapts to the surgeon insteadof having the surgeon adapt to the system

• Enhanced Functionality/Features: – 3D high definition flat panel display

– Custom designed master controllers

– Second display for delivering ancillaryinformation

– Data collection and analytics



• Designed for optimal configurability for a variety ofsurgical indications and to be maneuvered aroundoperating room and surgical centers

• Incorporates an Insertion Tube for insertion into apatient during a surgical procedure, including:

– A stereoscopiccamera module

– Insertable roboticinstruments

Robotic Platform/Patient Cart

SPORT™ Surgical System Patient Cart CAD Rendering



Camera Module and Instruments

• Stereoscopic Camera Module

• Custom design allows a 19 mm diameterInsertion Tube enabling an incision size ofapproximately 25 mm

• Multi-direction movement

• Collapsible/Expandable

• Pan and Tilt

• Digital Zoom

• Robotic Instrument Arms• Multi-articulating to allow

for “snake-like” movement

• Single-patient use tool tips



• Single-Patient Use Tool Tips – Sterile

– No Reprocessing Required

– First Use Quality Every Case

• Reposable Robotic Instruments

– More use cases for eachinstrument arm

– Reduces per case cost

SPORT™ Tools



11

Training Curriculum

Cognitive pre-training Knowledge Acquisition

Psychomotor skills training Technical Skills Acquisition

Team training Choreography & Communication

Troubleshooting Crisis Mitigation

Overview of safety Optimal Skills and Teamwork

Post-Training Assessment

Design assessment tools

Define: skills, setting, scoring

method, scenarios, & train

raters

Validate assessment toolsConstruct Validity, Predictive

Validity

Learning Experiences

Assessment Tools

SPORT™ Training & Assessment

• Training curriculum and and post-training assessmentprograms under development with the James and Sylvia Earl,Simulation to Advance Innovation and Learning (SAIL) Centerat Anne Arundel Medical Center (AAMC) in Annapolis, MD



12

• FDA:

– July 2015: Participated in Open Workshop on Robotic Assisted Devices sponsored by the FDA

– September 2015: Engaged a Contract ResearchOrganization (CRO) to implement Early Feasibility

Human Study – What’s Next (Anticipated): Q3 2016 Pivotal Human

Clinical Trial commenced

• CE Mark:

– July 2015: Contracted with a Notified Body

– What’s Next (Anticipated): Q2 2016 - Audit for CE Markapproval commenced

Regulatory



13

Intellectual Property

Patents: What Titan has today*

11 Patents from Technology Developed Internally or Exclusively Licensed

• Laparoscopic Surgery Generally – Use of Magnetics

• Robotic Surgery Instruments

• Robotic Surgery Input Control

• Laparoscopic Surgical Stapler

Patent Applications: What Titan has in the pipeline*

21 Patent Applications from Technology Developed Internally or Exclusively Licensed

• Robotic Surgery Instruments

• Robotic Surgery Input Control

• Robotic Surgery Control Systems andIntelligence

• Robotic Surgery Patient Cart

• Robotic Surgery Access

• Laparoscopic Surgical Stapler

*As of November 24, 2015



14

Development Milestones Estimated Cost(in U.S. $)

Schedule forMilestone

Completion

Comments

Alpha commercial prototype design complete(Design of prototype suitable for ongoing tissuetesting)

- Q1 2014 Completed

Alpha commercial prototype built - Q2 2014 Completed

Tissue testing(Testing performance of individual features andfunctionality)

- Q2 2014 Completed

Design and test of feasibility prototype complete(Demonstrate feasibility for next generation

console and advanced instruments)

- Q1 2015 Completed

Units built and ready for engineering verification(Prototype is formally tested to meet previouslydefined specifications)

Build 2 engineering verification units

Build 5 first in-human units

(2 milestones)

$14 million

$9 million

Q4 2015

Expected

Q1 2016

Expected

Development Milestones



15

Development Milestones Estimated Cost(in U.S. $)

Schedule forMilestone

Completion

Comments

Development Milestones – Cont’d

Early human feasibility report complete(Human clinical cases utilizing units are testedunder engineering verification)

$24 million

(2 milestones)

Q2 2016

Expected

First in human studiesconfirm capabilities of

SPORT™ Surgical System

for expanded use.

Build 4 additional humanclinical trial units.

Audit for CE Mark approval commenced Q2 2016

Expected

Pivotal human clinical trial commenced $5 million Q3 2016

Expected

Pivotal human clinical trial completed and510(k) application submitted to FDA

$5 million

(3 milestones)

Q4 2016

Expected

Outside U.S. commercial launch(Pending CE Mark approval)

Q4 2016

Expected

U.S. commercial launch

(Pending 510(k) market clearance)

Mid-2017

Expected

TOTAL U.S. $57 million



16

*Fully diluted includes, under the Treasury Stock method, an additional 2,775,151 options with a weighted-average exercise price of

CDN $1.32, as well as common shares issued as result of the public offering, November 16, 2015 and the private placement of

November 23, 2015.

In addition, 3,665,900 warrants (@CDN $1.85 expiring December 10, 2015), 5,121,500 warrants (@CDN $2.00 expiring June 21,

2016), 3,484,500 warrants (@CDN $1.75 expiring December 22, 2016), 390,729 warrants (@CDN $1.77 expiring March 14, 2017),

5,260,705 warrants (@CDN $1.25 expiring March 13, 2018), 8,317,856 warrants (@CDN $2.00 expiring February 19, 2017),

12,346,914 warrants (@CDN $2.75 expiring April 23, 2017) and an additional 7,012,195 warrants (@CDN $1.60 expiring November

16, 2020).

Financial Snapshot

TMD (TSX), TITXF (OTCQX)

(in US Dollars except warrants

and options exercisable in

Canadian dollars)

September 30, 2015

Share Price (TMD) $1.36

Cash, cash equivalents andshort-term investments

$10.1 million

Shares outstanding 116.5 million (117.4 millionFD*)

Market value 158.4 million ($159.7 millionFD*)

Management ownership(September 30, 2015)

6.18%



17

Stock Performance - TSX

$0.00

$50.00

$100.00

$150.00

$200.00

$250.00

$300.00

$350.00

$400.00

2009 2010 2011 2012 2013 2014

Titan Medical Inc. - Common Share Price Performance

Titan Medical Inc.

S&P/TSX Composite Index

As at December 31

31-Dec-09 31-Dec-10 31-Dec-11 31-Dec-12 31-Dec-13 31-Dec-14

Titan Medical Inc. 100.00 355.00 337.50 300.00 237.50 350.00

S&P/TSX Composite Index 100.00 114.45 101.78 105.85 115.97 124.57

The following table shows the value of CDN$100 invested in Common Shares on December 31, 2009 compared to CDN$100 invested inthe S&P/TSX Composite Index*:*All amounts in Canadian $.



18

Stock Ranking – OTCQX 2014

The 2015 OTCQX®

Best 50 is a rank ing of top per fo rming companies on theOTCQX Best Marketplace in 2014 based on one-year share price performanceand average daily dollar volume growth.

Source: http://www.otcmarkets.com/content/doc/2015-OTCQX-Best-50.pdf

Titan Medical Corporate Presentation.

Documents